The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
The microbial world has been a rich source of medicines, but our ability to explore the full potential of the microbes both in us and around us has been limited by technology and the difficulty of culturing most microbes in a lab. Biosortia Microbiomics has developed a platform for finding, amplifying, and screening microbes as a potential source of novel, small molecule drugs. We spoke to Ross Youngs, CEO and founder of Biosortia, about the case for exploring various microbiomes to discover new small molecule drugs, how the company’s platform technology enables it to investigate a much broader range of microbes, and its business model for capitalizing on the discoveries it makes.
E016: Scaling and breakthrough with Ross Youngs
In this episode, Artur and Marian discuss what is required for scaling technologies and how to achieve breakthroughs. To give a practical example, they interview Ross Youngs, CEO, and founder of Biosortia, who describes his company’s scaling and breakthrough in the field of microbiome harvesting.
You can find out more about Biosortia Microbiomics here – https://biosortia.com/
This podcast is also available on https://bdr.show and your favorite podcast platforms. Subscribe today to make sure you don’t miss any future episodes!
If you’d like to contact us with comments, suggestions, or complaints, email us at po*****@co*******.llc
Master Strategic Change – Focus on Culture and Behavior
Culture & Innovation: Mining the Human Microbiome- Accelerating Research & Discovery
Join me and Ross Youngs, a successful innovator, serial entrepreneur, and the founder and CEO of Biosortia, Inc. – Microbiomics, for great insights on how AI and technology support academia, accelerate discovery, and what this means for humanity.
Innovation is what sets market leaders ahead, but most business owners view it as a luxury. It can feel like your day-to-day responsibilities are too demanding to focus on innovation.
If you want to succeed, you need to start with an innovative strategy that solves problems for your customers and for you. Our guest today can help you do just that.
Interview of Microbiome Power with Ross Youngs, CEO of the Biosortia Microbiomics.
Biosortia Microbiomics is developing genuinely disruptive technology for the mining of microbiomes. It was our great pleasure to have the opportunity for an interview with Mr. Ross Youngs, Founder, and CEO of Biosortia.
Today’s guest is Ross Youngs, CEO of Univenture and a long-time entrepreneur. He has successfully taken businesses from small investments to hundreds of millions of dollars in revenue. Today’s we will be talking about disruptive innovation and how it’s not a game that is only for the biggest companies like Microsoft or Apple but is actually something you can follow with a couple of key steps.
Ross has spent over 30 years inventing products, technologies, and processes for a variety of industries, and holds over 75 patents worldwide. He is driven to innovate by a focus on what is better, faster, and less expensive.
Ross’ recent major innovations include an R&D 100 Award for collaboration on biopolymer technologies. In 2009, Biosortia was awarded a $6 million ARPA-E grant for its algal harvesting technology, which helped lead to the development of Biosortia’s drug discovery platform.
After listening to today’s episode, check out https://www.biosortia.com/ to learn more about Ross Youngs and Biosortia.
Rock Stars of R&D, Episode 29, Ross Youngs
An Engineering Entrepreneur in Technology and now as CEO of BIOSORTIA, Microbiomes, and Microbiomics, Ross spent a career driving breakthrough technologies to fruition and acceptance.
Ross Youngs has spent over 30 years inventing products, technologies, and processes for a variety of industries, and holds over 75 patents worldwide. He is driven to innovate by a focus on what is better, faster, and less expensive. Ross’ recent major innovations include an R&D 100 Award for collaboration on biopolymer technologies. In 2009, Biosortia was awarded a $6 million ARPA-E (U.S. Dept. of Energy R&D) grant for its algal harvesting technology, which helped lead to the development of Biosortia’s drug discovery platform.
The Donna Drake Show Live It Up with Ross O Youngs on Biosortia Pharmaceutical.
Extract Value from Natural and Chemically Modified Compounds.
Pre-clinical portfolio of microbiome-derived immune-modulating peptides and other small molecules with exclusive technologies and the scientific expertise for discovering, expanding, and advancing a valuable IO/I pipeline.